• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

ProQR Therapeutics NV (PRQR)

Ordinary Shares
Sell: $1.50|Buy: $1.54|Change: 0.05 (-3.14%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

Address

Zernikedreef 9
Leiden
NLD
2333 CK

Telephone

+1 3188 1667000

Website

https://www.proqr.com

Sector 

Healthcare

Forecast key dates

NameKey Date
ProQR Therapeutics NV Fourth Quarter Earnings Results for 20262027-03-12T00:00:00
ProQR Therapeutics NV Annual Report for 20262027-03-12T00:00:00
ProQR Therapeutics NV Third Quarter Earnings Results for 20262026-11-06T00:00:00
ProQR Therapeutics NV Second Quarter Earnings Results for 20262026-08-07T00:00:00
ProQR Therapeutics NV Annual General Meeting for 20262026-06-03T15:30:00
ProQR Therapeutics NV First Quarter Earnings Results for 20262026-05-08T00:00:00
ProQR Therapeutics NV First Quarter Earnings Conference Call for 20262026-05-08T00:00:00
ProQR Therapeutics NV Fourth Quarter Earnings Results for 20252026-03-12T00:00:00
ProQR Therapeutics NV Annual Report for 20252026-03-12T00:00:00
Citizens Life Sciences Conference2026-03-11T15:25:00

Previous key dates

NameKey Date
ProQR Therapeutics NV Fourth Quarter Earnings Results for 20252026-03-12T00:00:00
ProQR Therapeutics NV Annual Report for 20252026-03-12T00:00:00
Citizens Life Sciences Conference2026-03-11T15:25:00
8th Annual Evercore Healthcare Conference2025-12-04T08:20:00
ProQR Therapeutics NV Third Quarter Earnings Results for 20252025-11-06T00:00:00
Virtual Investor and Analyst Event on AX-08102025-11-03T11:30:00
ProQR Chardan’s 9th Annual Genetic Medicines Conference 20252025-10-21T13:00:00
ProQR Therapeutics NV Second Quarter Earnings Results for 20252025-08-07T00:00:00
ProQR Therapeutics NV Annual General Meeting for 20252025-06-03T15:30:00
The Citizens Life Sciences Conference2025-05-08T11:30:00
ProQR Therapeutics NV First Quarter Earnings Conference Call for 20252025-05-08T00:00:00
ProQR Therapeutics NV First Quarter Earnings Result for 20252025-05-08T00:00:00
ProQR Therapeutics NV Fourth Quarter Earnings Results for 20242025-03-13T00:00:00
ProQR Therapeutics NV Annual Report for 20242025-03-13T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.